A Phase II, Randomized, Multi-center, Two Part Study of the Safety and Efficacy of Double-blind, Placebo-controlled INX-08189 in Adjunctive Treatment With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Study Part A, and Open-label INX-08189 in Adjunctive (Interferon Free) Treatment With Daclatasvir and/or Ribavirin (Copegus) in Study Part B, in Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects.

Trial Profile

A Phase II, Randomized, Multi-center, Two Part Study of the Safety and Efficacy of Double-blind, Placebo-controlled INX-08189 in Adjunctive Treatment With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Study Part A, and Open-label INX-08189 in Adjunctive (Interferon Free) Treatment With Daclatasvir and/or Ribavirin (Copegus) in Study Part B, in Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 30 Jun 2014

At a glance

  • Drugs BMS 986094 (Primary) ; Daclatasvir; Peginterferon; Ribavirin
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 23 Aug 2012 Status changed from suspended to discontinued.
    • 06 Aug 2012 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
    • 01 Aug 2012 Administration of BMS 986094 has been suspended due to the emergence of a serious adverse event.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top